Accelerate Diagnostics Inc Q3 2024 Earnings Call Highlights Strategic Advances Amid ...
AXDX Stock | USD 1.58 0.01 0.64% |
Slightly above 52% of Accelerate Diagnostics' investor base is interested to short. The analysis of overall sentiment of trading Accelerate Diagnostics stock suggests that many investors are impartial at this time. Accelerate Diagnostics' investing sentiment can be driven by a variety of factors including economic data, Accelerate Diagnostics' earnings reports, geopolitical events, and overall market trends.
Accelerate |
Despite a net loss, Accelerate Diagnostics Inc reports significant improvements in gross margin and strategic progress in clinical trials and product approvals.
Read at finance.yahoo.com
Accelerate Diagnostics Fundamental Analysis
We analyze Accelerate Diagnostics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Accelerate Diagnostics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Accelerate Diagnostics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Gross Profit
Gross Profit Comparative Analysis
Accelerate Diagnostics is currently under evaluation in gross profit category among its peers. Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Accelerate Diagnostics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Accelerate Diagnostics stock to make a market-neutral strategy. Peer analysis of Accelerate Diagnostics could also be used in its relative valuation, which is a method of valuing Accelerate Diagnostics by comparing valuation metrics with similar companies.
Peers
Accelerate Diagnostics Related Equities
SGHT | Sight Sciences | 4.59 | ||||
LUNG | Pulmonx Corp | 3.90 | ||||
ELMD | Electromed | 2.54 | ||||
AXGN | Axogen | 1.64 | ||||
NPCE | Neuropace | 0.80 | ||||
AORT | Artivion | 0.61 | ||||
CVRX | CVRx | 0.60 | ||||
OFIX | Orthofix Medical | 0.32 | ||||
KIDS | Orthopediatrics Corp | 0.30 | ||||
SRDX | SurModics | 0.18 | ||||
ITGR | Integer Holdings | 0.08 | ||||
CNMD | CONMED | 0.48 | ||||
ANIK | Anika Therapeutics | 0.51 | ||||
IRMD | Iradimed | 0.55 | ||||
LIVN | LivaNova PLC | 1.56 | ||||
AVNS | Avanos Medical | 2.22 |
Additional Tools for Accelerate Stock Analysis
When running Accelerate Diagnostics' price analysis, check to measure Accelerate Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Accelerate Diagnostics is operating at the current time. Most of Accelerate Diagnostics' value examination focuses on studying past and present price action to predict the probability of Accelerate Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Accelerate Diagnostics' price. Additionally, you may evaluate how the addition of Accelerate Diagnostics to your portfolios can decrease your overall portfolio volatility.